Overview

CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

Status:
Terminated
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Semapimod